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Synopsis
ABCG2 is an ABC (ATP-binding cassette) transporter with a physiological role in urate transport in the kidney and
is also implicated in multi-drug efflux from a number of organs in the body. The trafficking of the protein and the
mechanism by which it recognizes and transports diverse drugs are important areas of research. In the current study,
we have made a series of single amino acid mutations in ABCG2 on the basis of sequence analysis. Mutant isoforms
were characterized for cell surface expression and function. One mutant (I573A) showed disrupted glycosylation and
reduced trafficking kinetics. In contrast with many ABC transporter folding mutations which appear to be ‘rescued’ by
chemical chaperones or low temperature incubation, the I573A mutation was not enriched at the cell surface by either
treatment, with the majority of the protein being retained in the endoplasmic reticulum (ER). Two other mutations
(P485A and M549A) showed distinct effects on transport of ABCG2 substrates reinforcing the role of TM helix 3 in
drug recognition and transport and indicating the presence of intracellular coupling regions in ABCG2.
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INTRODUCTION
ABCG2 is one of the five members of the G-subfamily of human
ATP-binding cassette (ABC) transporters. The protein is local-
ized to numerous epithelial tissues within the body, including
much of the gastrointestinal tract. It is also found in the kid-
neys, the placenta and within the endothelium of the vessels of
the blood–brain barrier [1]. It is one of the three human ABC
transporters that are well characterized as multi-drug pumps, i.e.
having a broad specificity for substrates that encompasses mo-
lecules with different chemical structures and physico-chemical
properties [2]. This broad substrate specificity, together with the
tissue distribution data, implicates ABCG2 as having a protective
role by exporting xenobiotic compounds from organs. As such it
is a major factor in the pharmacokinetics of prescribed drugs in-
cluding statins [3] and fluoroquinolone antibiotics [4]. Moreover,
ABCG2 is able to transport many anti-cancer and anti-neoplastic
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agents and up-regulated expression of ABCG2 is observed in
some forms of drug-resistant cancer [5]. A further physiological
role has come from the demonstration that the most common
polymorphism of ABCG2 (rs2231142) is associated with gout
and that ABCG2 is a transporter of urate in the kidneys [6,7].
ABCG2 (in common with other members of the human ABCG
sub-family) has two topological features that are distinct from
many other eukaryotic ABC transporters. Firstly, it is a ‘half
transporter’, being composed of only a single transmembrane
domain (TMD) and a single nucleotide-binding domain (NBD)
in the polypeptide chain. This has led to the assertion that ABCG2
must at least homo-dimerize in order to function, although the
exact oligomeric state is unknown [8–10]. Another impediment
to our understanding of ABCG2 is that its domains are in the re-
verse order compared with the majority of ABC proteins. In other
words, the NBD is preceded by the TMD, whereas the typical
configuration has the TMD N-terminal to the NBD. This com-
bination of features means that it is impossible to infer structure:
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function information by comparison with other, better character-
ized human multi-drug pumps such as ABCB1/P-glycoprotein
[11]. Notwithstanding this, a number of homology models for
ABCG2 exist but these may not be an ideal structural framework
to explain data or make new predictions about important residues
and regions [12,13].
To date, ABCG2 substrate interaction has been characterized
by radioligand-binding analysis and has been identified to have a
complex network of drug interactions whose affinities are altered
by the interaction of NBDs with ATP [14,15]. The spatial loc-
alization of drug interaction site(s) is unknown, with only one
well-characterized example of a residue known to impact upon
drug selectivity. Residue 482 in transmembrane helix (TM) 3 of
the TMD is an arginine in the wild-type (WT) sequence, but a
drug selected cell line expressing a mutant version (where the ar-
ginine is replaced by glycine; R482G) shows a broader resistance
profile including doxorubicin and rhodamine 123 in its substrates
[16–18]. Structurally, there are two EM studies of ABCG2. Al-
though these are limited in their resolution, they are able to con-
firm that the transporter can form stable homo-oligomers and
undergoes conformational changes in response to drug binding
[10,19].
Our group is interested in understanding the structure and
function of ABCG2. Due to the limitations of using homology
models of ABCG2 based upon other ABC exporters, we have
adopted a sequence analysis based approach to identify residues
in ABCG2 for mutational analysis and characterization. Using
co-evolution analysis (i.e. the correlated changes of amino acids
at spatially distinct positions in the primary sequence), we have
mutated several amino acids in the NBD and TMD of ABCG2.
Analysis of these mutated isoforms enabled us to identify residues
that contribute to drug binding or allosteric communication and
to trafficking of ABCG2 to the membrane.
MATERIALS AND METHODS
Molecular biology
All molecular biology enzymes were from either New England
Biolabs (NEB) or Promega. The mutant isoforms were gener-
ated in an N-terminally His12 tagged version of WT ABCG2 in
pcDNA3.1( + ). The mutants were constructed using Quikchange
II technology (Stratagene) employing complementary primers
(Sigma) each encoding the mutation of interest. Primers also
included a further mutation, synonymous in terms of translation,
to alter the restriction digest profile if the introduction of the
mutant did not accomplish this. All primers are listed in Supple-
mentary Table S1. Following PCR, competent DH5α cells were
transformed with the reaction products and colonies screened for
plasmids showing the modified restriction digest profile. Super-
folder GFP (sfGFP)-tagged variants of ABCG2 were constructed
by sub-cloning the ABCG2 coding region into a pre-existing
p3.1zeo_sfGFP-ABCG2 vector (Wong and Kerr, unpublished).
All plasmids were sequenced across the entirety of the ABCG2
cDNA to ensure the fidelity of mutagenesis and sub-cloning.
Cell culture
Human embryonic kidney (HEK) 293T cells were maintained in
Dulbecco’s Modified Eagle Media (DMEM; Sigma) supplemen-
ted with 10 % foetal calf serum (FCS; Gibco) and 100 units/ml of
penicillin/streptomycin (Invitrogen) at 37 ◦C in a humidified 5 %
CO2 incubator. Cells were transfected using polyethyleneimine
(linear PEI, Polysciences) [20]. For six-well dishes cells were
plated at 250000–300000 per well, 24 h prior to transfection.
Three hours prior to transfection, the media was replaced by a
5 % serum containing DMEM. Plasmid DNA (2–4 μg) was mixed
with PEI at a nitrogen–phosphorus molar ratio of 15:1 [20] and
was added to the cells within a few minutes of complex forma-
tion. One day later, the media was replaced by DMEM–10 % FCS.
For flow cytometry transfection was scaled up to 10-cm dishes.
Stable HEK293T cell lines expressing sfGFP–ABCG2 were ob-
tained by supplementing media 24 h post transfection with zeocin
(Sigma; 200 μg/ml) for 7–14 days until cell death was complete
in untransfected cells and when zeocin-resistant colonies had de-
veloped in plasmid transfected cells. Subsequently stable, vari-
able expression level cell lines were passaged in media containing
40–50 μg/ml zeocin.
SDS/PAGE and immunoblotting
Cells were harvested by repeat pipetting and then centrifuged
(14 000 g, 1 min), washed in ice-cold PBS and re-pelleted as
above. Cells were resuspended in ice-cold PBS supplemen-
ted with protease inhibitors (Complete EDTA-free Protease In-
hibitor, Roche) and lysis was performed by 3 × 10 s bursts
with a chilled probe sonicator (Microsonix). Protein concen-
tration was determined using a modified Lowry protein assay
(Biorad) and cell lysates (30 μg of protein) were resolved by
SDS/PAGE [8 %–10 % (w/v) acrylamide]. Following transfer on
to nitrocellulose membrane, ABCG2 was detected using BXP-
21 (Merck Biosciences) at a 1:500–1:2000 dilution in PBS/5 %
(w/v) skimmed milk powder/0.1 % (v/v) Tween, followed by a
horseradish peroxidase-conjugated rabbit anti-mouse secondary
antibody (1:2000; DAKO). Chemiluminescence was detected us-
ing Supersignal West Pico (Pierce). Parallel gels were loaded and
stained with Coomassie Brilliant Blue to ensure equal protein
loading.
Deglycosylation of ABCG2
Cell lysates (typically 30 μg of protein) were combined with
10× glycoprotein denaturing buffer (5 % SDS, 0.4 M DTT) and
H2O to make a 10 μl of reaction volume. The samples were then
denatured by heating at 100 ◦C for 10 min. Following this, the
total reaction volume was adjusted to 20 μl by adding 10× G7
reaction buffer [0.5 M sodium phosphate (pH 7.5 at 25 ◦C)], 10 %
NP40, H2O and 1–2 μl of peptide–N-glycosidase F (PNGaseF)
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and incubated at 37 ◦C for 1 h. Samples were then resolved by
SDS/PAGE.
Expression and functional analysis by flow
cytometry
HEK293T cells were analysed 36–40 hrs post-transfection by
flow cytometry. Cells were washed several times in ice-cold
sterile PBS and pelleted by centrifugation at 150 g for 5 min
at 4 ◦C. Pellets were resuspended in flow cytometry buffer [1 %
(v/v) BSA in phenol red-free DMEM] and aliquotted into flow
cytometry tubes as 100 μl of aliquots at a cell density of 1–2 × 106
cells per ml. For cell surface expression, cells were incubated with
5D3-PE (anti-ABCG2 antibody 5D3 conjugated to phycoeryth-
rin; R&D systems) at a 1:100 dilution. Parallel cell aliquots were
incubated with isotype control antibodies (IgG-PE; 1:100 dilu-
tion; MACS). For mitoxantrone (MX) accumulation cells were
incubated in the presence of 5 μM MX (Sigma) in the presence
or absence of fumitremorgin C (FTC; 10 μM; Sigma). Parallel
vehicle controls contained the maximum solvent concentration
[DMSO, <0.5 % (v/v)] to ensure that cell viability was unaffected
by the solvent. Following incubation at 37 ◦C with occasional
agitation for 30 min, cells were centrifuged at 300 g for 1–3 min
at 4 ◦C. The pellets were then washed twice with ice-cold flow
cytometry buffer and finally resuspended in 300–400 μl of buf-
fer, prior to analysis using a Beckman-Coulter XL-MCL Flow
cytometer. PE fluorescence was determined using excitation at
546 nm and emission at 578 nm and MX fluorescence measured
using excitation at 635 nm and emission at 670 nm. Flow cyto-
metry data were analysed using WEASEL v3.1 (The Walter and
Eliza Hall Institute of Medical Research).
Fluorescence microplate transport assay
Black-sided, clear-bottom 96-well plates (Greiner) were incub-
ated for 1 h in 10μg/ml poly-L-lysine (Sigma) before cells were
seeded at 40000 cells per well. Plates were incubated overnight at
37 ◦C and 5 % CO2 before media was replaced with phenol red-
free DMEM containing transport substrates [8 μM MX, rhod-
amine 123 (R123) or pheophorbide A (PhA)] in the presence or
absence of 0.5 μM Ko143 (Sigma). Cells were incubated for 1 h
at 37 ◦C and were subsequently washed once in PBS. Cells were
incubated for a further 1 h at 37 ◦C in phenol red-free DMEM
alone, supplemented with Ko143 where required. Cells were
washed with ice-cold PBS, before incubation with paraformalde-
hyde [PFA, 4 % (w/v), 15 min] and two final washes with PBS.
Cellular fluorescence was determined using a fluorescence plate
reader (MDC Flexstation). Fluorescence data were corrected for
values obtained from incubations with 1 % v/v DMSO, which
was the maximum solvent concentration used.
Fluorescence microscopy and live cell imaging
For live cell imaging, HEK293T cells stably transfected with
sfGFP–ABCG2 isoforms were plated on to MatTek glass-
bottomed 35-mm dishes at least 24 h prior to imaging and
were visualized on a Zeiss LSM 710 (Zeiss) confocal micro-
scope, using a plan-apochromat 63×/1.40 Oil Ph3 M27 ob-
jective and argon laser. For immunofluorescence determina-
tion of the localization of the I573A isoform, cells were fixed
on cover slips with 4 % PFA in PBS for 5 min at room tem-
perature before treatment with 50 mM NH4Cl for 10 min to
quench the free aldehyde groups of the fixative preventing auto-
fluorescence [21]. Cells were then washed twice with ice-cold
PBS and incubated in 0.5 % (w/v) BSA in PBS for 15 min
at room temperature to prevent non-specific antibody interac-
tion. Following blocking, cells were incubated for 1 h with anti-
calnexin primary antibody (Sigma) prepared at 1:500 dilution
in blocking buffer. The primary antibody solution was removed
and the cells washed several times with blocking buffer. Cells
were then incubated in secondary antibody (donkey anti-goat
monoclonal antibody conjugated to AlexaFluor 647 red fluor-
escent dye; Invitrogen), at a 1:1000 dilution in blocking buffer.
Cells were washed several times with blocking buffer and once
with PBS, then mounted on to microscope slides with Fluoro-
Gel mounting medium (GeneTex), before confocal microscopy
as above.
Bioinformatics analysis
All sequence identification and alignment was performed using
standard web-based servers BLAST, ExPASy and ClustalW.
Analysis of residues under co-evolutionary selection was
performed using the web server (http://coevolution.gersteinlab.
org/coevolution/), described in [22].
Experimental data analysis
All numerical data manipulations were performed using Excel or
GraphPad Prism and statistical analyses performed using Prism.
All statistical tests are detailed in appropriate figure legends and
significance was judged at P-values less than 0.05.
RESULTS
A number of mutations in ABCG2 have been constructed pre-
viously to analyse protein function [16,23,24]. We embarked on
a directed mutagenesis strategy to identify other amino acids
outside of typical conserved ABC transporter regions that are
important for function, using co-evolutionary sequence analysis
(Supplementary Figure S1; [22]). A residue (i) in a multiple se-
quence alignment is co-evolving with another residue (j) in that
alignment if it can be shown that the evolutionary changes oc-
curring at position i are correlated with amino acid substitutions
at position j. This has been shown to be a useful approach to
identify pairs of important residues when combined with struc-
tural data [25,26]. In the absence of high resolution structural data
for ABCG2 and with no compelling homology models [1,11],
we used co-evolutionary analysis algorithms to identify residues
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Figure 1 Location of the residues selected for mutation in ABCG2
The transmembrane topology of ABCG2 is represented according to the data of Mao and colleagues [30], with approximate
membrane plane indicated by the dashed line. TM residues are shaded purple and extramembraneous residues in lime.
Residues for mutation are on an orange background, numbered and indicated using the single-letter amino acid code.
Local sequence context and NBD sequence motifs have been shown for ease for reference.
within the ABCG sub-family that are involved in a ‘network’
of co-evolutionary relationships with multiple other residues.
Our reasoning was that these amino acids may be central to
the function of ABCG2, be that in coupling of the NBDs to the
TMDs or the binding of substrates and inhibitors. Three such
co-evolutionary analyses were performed (using a web-based in-
terface) [22] on a multiple sequence alignment of over 100 ABCG
family sequences, namely statistical coupling analysis [25], Chi-
squared test [27] and explicit likelihood of subset co-variation
[28].
This analysis (Supplementary Figure S1; Supplementary Table
S2) allowed us to identify eight amino acids (Figure 1) which are
frequently involved in co-evolutionary relationships (‘coupled’)
with other residues in ABCG2. Notably, all these are coupled
to residues in different domains, i.e. the NBD residues identi-
fied are coupled to residues in the TMDs and vice versa perhaps
suggestive of a role in inter-domain communication. Two of the
residues are located in the NBD; Met131 which is five amino acids
C-terminal from the conserved Q-loop [29] and Ser195 which is
located five amino acids C-terminal to the signature motif [29].
The other six amino acid mutations are in the TMD and, accord-
ing to the experimentally determined topology map of Mao and
colleagues [30], are located as follows: Lys453 in the first turn
of TM2, Lys473 in the short intracellular loop between TM2 and
TM3, Pro485 is one turn of α-helix C-terminal to the function-
ally significant Arg482 in TM3, Met549 is in the long intracellular
loop between TM4 and 5, Trp564 is the very intracellular end of
TM5 and Ile573 is located in TM5. We made individual substi-
tutions of each amino acid to alanine: M131A, S195A, K453A,
K473A, P485A, M549A, W564A and I573A. A further three
control mutations were analysed, namely a substitution of lys-
ine to alanine in the Walker-A motif (K86A), a substitution of
glutamate to glutamine in the Walker-B motif (E211Q) and a
substitution of asparagine to glutamine at the site of glycosyla-
tion (N596Q). All 11 mutants are displayed schematically in
Figure 1.
To identify whether the mutants had any dramatic effect on the
expression and localization of ABCG2, we transiently transfected
plasmid DNA encoding His12-ABCG2 isoforms into HEK293T
cells and analysed using flow cytometry with antibodies re-
cognizing the extracellular 5D3 epitope. The majority of the
mutants were present at the cell surface at comparable levels
to the WT (i.e. N-terminally His12-tagged ABCG2) protein (e.g.
Figures 2B–2D). Analysis of the expression level (given by the ra-
tio 5D3-PE fluorescence labelling compared with IgG–PE fluor-
escence labelling) of all mutants suggested that, of the novel
mutants examined in the present study, only I573A had reduced
cell surface expression (Figures 2E and 2F). To ensure that any
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Figure 2 Transient expression of His12–ABCG2 and isoforms in HEK293T cells
Flow cytometry analysis of cell surface expression 40 h post-transfection (A–E). Black lines represent distributions of
cellular fluorescence following labelling with PE-conjugated anti-ABCG2 antibody 5D3. Grey lines represent isotype control
labelling. (A–E) Representative data of the empty vector, WT or named isoforms. The relative surface expression (F) was
quantified as the ratio of the mean fluorescence values in the presence of 5D3 to the mean fluorescence value in the
presence of isotype control antibodies. Mean (+− S.E.M.) is shown for at least four independent transfections. (G) Western
blotting of total ABCG2 expression was determined by resolving 30 μg of whole cell lysate on 10% w/v acrylamide gels
and probing with BXP-21 antibody. A representative image of at least four independent experiments is shown.
variability in expression of I573A was not a reflection of the con-
formational sensitivity of the 5D3 antibody [31], we performed
western blotting of whole cell lysates with the BXP-21 antibody
which recognizes an intracellular epitope. This confirmed that
I573A was expressed at reduced levels compared with other iso-
forms (Figure 2G; I573A expression is essentially undetectable
in this exposure).
The failure of one of the isoforms (I573A) to effectively reach
the cell surface piqued our interest as membrane trafficking is
clearly of cellular and clinical relevance, both for ABCG2 and
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Figure 3 His12-I573A shows impaired glycosylation
(A) Following transient transfection cell lysates (30 μg) were resolved
on 10% w/v acrylamide gels and blotted with BXP-21 antibody. Trans-
fection reagent only (PEI) served as negative control, WT His12–ABCG2
and His12–M131A serve as positive controls. His12–N596Q is a glyc-
osylation defective form of ABCG2. His12–I573A is exclusively present
at an intermediate molecular mass at 24 h and even at 48 h the ma-
jority of His12–I573A isoform is not the mature molecular mass. (B).
Cell lysates were obtained 24 and 48 h post transfection, denatured
and then incubated in the presence or absence of PNGaseF to remove
glycosylation before western blotting. His12–N596Q shows no change
in molecular mass upon PNGaseF treatment. By contrast, the lower mo-
lecular mass band following transfection with the His12–I573A isoform
shows a small (estimated < 5 kDa) change in molecular mass upon
PNGaseF treatment indicative of the removal of core glycosylation. WT
and a representative other mutant (His12–M131A) are fully glycosylated
at both 24 and 48 h post transfection. Data are representative of at
least three independent transfections.
for other ABC transporters [6,32]. Examination of a time course
of protein expression (24 and 48 h post-transfection respectively)
confirmed that His12I573A was being expressed (Figure 3A),
but that the protein appeared to have a reduced molecular mass
compared with WT His12ABCG2 and a fully functional mutant
isoform (His12M131A–functional data in Figure 5). Indeed the
molecular mass was closer to that of the isoform His12N596Q,
which cannot be glycosylated due to the removal of the sole
ABCG2 N-glycosylation site [33]. Effective glycosylation of
membrane proteins is critical in the regulation of their traffick-
ing to the cell surface; so, we further examined the glycosyla-
tion of the His12I573A isoform 24 and 48 h post-transfection
and demonstrated that the slight difference in molecular mass
between His12I573A and His12N596Q is consistent with core
glycosylation (Figure 3B). Maturation of the His12I573A iso-
form to a fully glycosylated protein is clearly impaired with the
core glycosylated form still in evidence 48 h post transfection
(Figure 3B lower panel) compared with other isoforms which are
fully glycosylated at 24 h.
To enable live cell imaging of this isoform and to rule out
the possibility that these results are a consequence of a transient
transfection system, we generated stable cell lines expressing
WT and I573A isoforms of ABCG2 with an N-terminal sfGFP
extension. The presence of this tag does not affect localization
of the WT protein (Figure 4A), which is expressed almost ex-
clusively at the plasma membrane. Additionally, the drug export
function of the WT isoform is unaffected by N-terminal tagging
(Figure 6A) [8]. For sfGFP–I573A, the cellular fluorescence level
(i.e. a measure of protein expression) is reduced compared with
WT sfGFP–ABCG2 (compare intensity of Figure 4A with Fig-
ure 4B obtained using identical image acquisition and processing
conditions), in agreement with data from transient expression
of untagged isoforms (Figure 2). Moreover, sfGFP–I573A is
retained in perinuclear and reticular intracellular compartments
with very little protein at the cell surface. Co-localization of
the sfGFP–I573A isoform was demonstrated with anti-calnexin
antibodies confirming the ER retention (Figure 4C). ‘Rescue’ of
mis-folded and mis-localized membrane proteins is of growing
clinical importance [6,34,35] and has been achieved in vitro with
either chemical chaperones (small molecules which modulate
either the folding of the protein or the ER recognition of
mis-folded proteins) or by reducing the rate of protein translation
by lowering the cell culture temperature. We investigated
both of these possibilities with the sfGFP–I573A isoform and
demonstrated that neither incubation at 30 ◦C (Figure 4D, right
hand panel), nor incubation with the chaperone 4–phenylbutyrate
rescued the cell surface expression of I573A (Figure 4D, left
hand panel), although the latter did result in a qualitatively
higher expression of sfGFP–I573A (compare Figure 4B right
hand and 4D left hand panel which are obtained under identical
image capture and processing settings on the same day).
The transport function of His12-ABCG2 isoforms was invest-
igated initially by flow cytometry of transiently transfected cells,
taking advantage of the ability of ABCG2 to export the fluores-
cent drug MX and the availability of a specific ABCG2 inhib-
itor FTC [36,37]. Using flow cytometry, a rightward shift in the
cellular fluorescence profile is expected upon incubation with
FTC. The mutants could be classified into two categories, which
are shown in Figure 5. Firstly, there was a group of five mutants
which showed FTC-inhibited MX export comparable to WT pro-
tein (e.g. M131A, S195A, K453A, K473A, W564A; M131A
data shown in Figure 3C). Secondly, there were a pair of mutant
isoforms which showed little or no FTC-mediated inhibition of
MX export (i.e. having high accumulation of MX even in the
absence of FTC) but normal ABCG2 surface protein expression
(P485A and M549A; P485A data shown in Figure 5D). These
two mutants behaved in this assay in essentially the same way as
the K86A and E211Q catalytically inactive mutants (result not
shown).
To investigate further the two TMD mutations with impaired
drug transport (M549A and P485A), we generated stable ex-
pressing cell lines expressing sfGFP-tagged isoforms. sfGFP-
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Figure 4 sfGFP–I573A is retained in the endoplasmic reticulum (ER) and cell surface expression is not rescued by low
temperature incubation
To visualize trafficking of I573 in live cells, stable cell lines expressing WT and I573A isoforms of ABCG2 with an N-terminal
sfGFP tag were generated and examined by confocal imaging. The majority of WT ABCG2 is present at the cell surface (A,
phase and merged image), whereas the majority of I573A is retained intracellularly (B). (C) Immunostaining of cells with
anti-calnexin antibodies (red, left hand panel) shows significant co-localization of the sfGFP–I573A fluorescence signal
(green, middle panel and yellow in the merged image, right hand panel) indicative of the retention of the majority of
sfGFP–I573A in the ER. (D) Incubation of cells with the chemical chaperone 4-phenylbutyrate (5 mM) showed an increase
in overall expression but no effect on localization (left hand panel). (D) Incubation of sfGFP-I573A expressing cells at 30 ◦C
had little effect on the localization of the I573A to the cell surface (right hand panel). Scale bar is 10 μm.
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Figure 5 Functional analysis of His12–ABCG2 isoforms
Functional analysis was undertaken by flow cytometry 40 h post transfection determining the cellular accumulation of MX
in the absence (grey line) or presence (black line) of FTC. Data are representative of at least four independent transfections
and reflect negative control data (empty vector, A), positive control data (WT ABCG2 expression, B), a mutant with normal
MX transport function (M131A, C) and a mutant with abrogated function but normal surface expression (P485A, D).
tagging was again without effect on the trafficking of the ABCG2
isoforms (Supplementary Figure S2). Transport function was
examined for three substrates (MX, PhA and rhodamine 123)
in a 96-well-based plate assay (Figure 6). None of the iso-
forms were able to transport R123, in accordance with previ-
ous data on the WT ABCG2 isoform [18]. Transport of MX
differed across the mutants (Figure 6A, ANOVA, P < 0.01).
Ko143-inhibitable transport of MX was observed in the
sfGFP–ABCG2–WT cell line (Figure 6A) with an approxim-
ately 5-fold increase in MX accumulation in the presence of
Ko143. sfGFP–P485A retained limited MX transport function
with a 1.6-fold increase in accumulation in the presence of
Ko143. sfGFP–M549A and the catalytically inactive sfGFP–
K86A isoform showed no Ko143-inhibited MX transport. With
PhA, neither sfGFP–K86A nor sfGFP–M549A showed Ko143-
inhibitable transport. In contrast, both sfGFP–ABCG2–WT and
sfGFP–P485A were able to export PhA in a Ko143-inhibitable
manner, with indistinguishable levels of Ko143 inhibition (Fig-
ure 6B), indicating positional specific effects on drug binding and
transport.
DISCUSSION
ABCG2 is one of three human multi-drug ABC transporters and
a combination of biochemical and biophysical investigations will
be required to fully understand transport. Presently, our abil-
ity to interpret data on ABCG2 mutations in terms of a structural
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model is very limited [11]. In the present study, we have therefore
utilized co-evolution analysis to identify candidate residues in
ABCG2 for mutation and characterization. Two of these residues
(Lys453 and Lys473) were previously mutated by Mao and col-
leagues [38] in a broader screen of positive charged residues
in/near TM2 with similar results to those obtained in the present
study. Of the eight residues we mutated, two resulted in altered
drug export function (P485A and M549A) and a further residue
(I573A) perturbs the trafficking and maturation of ABCG2 glyc-
osylation. These mutants have the potential for further analysis
in terms of understanding drug binding and transport, as well
as trafficking of ABCG2 and its regulation on the cell surface.
Intriguingly, two of the residues we have analysed (I573 and
P485A) are coupled to a residue Ser195, which can be mutated
to alanine without any apparent affect. Either this reflects that
the subtle serine to alanine substitution is well tolerated at this
intracellular residue or that this part of the NBD is coupled to
distinct areas of the TMD through different sets of intramolecular
interactions.
Residue co-evolution identifies pairs of residues whose evol-
ution is coupled [25,26]. In studies where there is a good struc-
tural model for a protein, the importance of coupled residues is
frequently examined by mutation of both the residues in the co-
evolving pair. In the current paper, we have taken a slightly differ-
ent approach and used co-evolution analysis to identify residues
that are frequently co-evolving with other residues. We hypo-
thesized that these residues may be involved in networks of al-
losteric or direct physical interactions, the disturbance of which
(by mutation) will manifest in altered structure and/or function.
Therefore, we mutated residues of interest to alanine as this is the
simplest amino acid from a secondary structural point of view
(as opposed to glycine which is likely to introduce greater local
structural flexibility in the peptide backbone).
One of the eight residues we mutated in the present study
(I573A) proved to have an effect on protein trafficking and mat-
uration, an effect previously seen with a mutation of a residue
located close to the intracellular side of TM1 [39]. In both tran-
siently transfected and stably transfected cells the protein was
delayed in reaching the cell surface, with a comparable delay
in glycosylation. I573A is located within TM5 in the model of
Mao and colleagues [30], although sequence based topological
models place it within the extracellular loop between TM5 and
TM6. Irrespective of its exact location, the effect of mutating
I573A on targeting and glycosylation is consistent with a critical
role for the TM5 and 6 region in the integrity of ABCG2 [40,41].
In contrast with some recent reports on the rescue of folding
mutants by chemical ‘correctors’ or by low incubation temperat-
ures [6,34,35], we could find not positive effect on I573A.
Two of the remaining residues we mutated (M549A and
P485A) affected drug export and provide some further evidence
for a role for TM3 in forming part of a drug-binding site on
ABCG2. Pro485 is one helical turn away from position 482, the
identity of which is known to be involved in substrate specificity.
Our data show that mutation of Pro485 in TM3 results in perturba-
tion of the drug export profile of ABCG2, with a dramatic reduc-
tion in MX transport capability but retention of PhA transport.
Figure 6 Residue Pro485 has a role in transport substrate spe-
cificity in ABCG2
HEK293T cells stably expressing sfGFP–ABCG2 and isoforms were ana-
lysed for transport of MTX (A) and PhA (B) using a fluorescence micro-
plate assay. Data are expressed as the ratio of the mean fluorescence
in the presence of transport substrate plus inhibitor (Ko143) compared
with the mean fluorescence in the absence of the inhibitor. Data rep-
resent the mean (+−S.E.M.) of at least four independent experiments.
Excitation and emission wavelengths were 607 and 684 nm for MX and
390 and 680 nm for PhA respectively.
A previous study [42] also showed P485A mutation resulted in
altered substrate specificity (although the majority of MX trans-
port was retained in that study [42]). Our resulting hypothesis
from these two studies is that residue 485, like 482, contrib-
utes directly to a drug-binding pocket, although a mutation of a
proline residue (which are known to cause functionally important
kinks in TMs) could result in local alterations to the protein struc-
ture that would explain the effects observed. The Met549 residue
would seem to be a poorer candidate for a direct contribution to
a drug-binding site. According to the experimentally-determined
topology model [30], this residue is located in the intracellular
loop between TM4 and TM5, where an effect on TMD–NBD
communication would be feasible if ABCG2 has intracellular
coupling helices, similar to those in other ABC transporters [43].
Further analysis of purified protein preparations will be required
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to determine whether the lack of function of the P485A and
M549A isoforms is due to impaired substrate binding (i.e. a dir-
ect effect on the drug-binding site) and/or impaired TMD–NBD
communication.
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